Ferdinandus de Looze

1 INTRODUCTION Allergic rhinitis (AR) affects 20%–30% of adults and up to 40% of children in Europe and the United States, making AR the most common atopic condition and the second leading cause of chronic disease.1 When poorly controlled, AR is recognized to have a major effect on quality of life, emotional well-being, sleep, daily activities, and productivity.2-4 Treatment options include Allergen Immunotherapy (AIT) as sole causal treatment, as well as various pharmacological options,...

This study was funded by Reckitt Benckiser. A Shephard is an employee of Reckitt Benckiser. R DeVito was a former employee of Reckitt Benckiser. Statistical support was provided by G Smith, a former employee of Reckitt Benckiser. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.